| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2018 | PCRX Pacira Biosciences, Inc. | Pace Gary W66 | Director | Buy | 4,500 | $46.18 | $207,810.00 | +15.9% | |
| Nov 16, 2018 | SIGA Siga Technologies Inc | Savas Paul G | Director | Buy | 5,000 | $5.58 | $27,900.00 | +2.1% | |
| Nov 16, 2018 | JNJ Johnson & Johnson | Gorsky Alex | Chairman, CEO | Sell | 264,465 | $145.96 | $38,600,967.60 | -44.0% | |
| Nov 16, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 200,000 | $113.74 | $22,747,000.00 | -0.2% | |
| Nov 16, 2018 | PCRX Pacira Biosciences, Inc. | Wicki Andreas71 | Director | Sell | 70,498 | $47.34 | $3,337,586.90 | -1.8% | |
| Nov 15, 2018 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 15,000 | $47.39 | $710,801.10 | -5.7% | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Brynjelsen Sean | President &CEO | Buy | 10,000 | $6.00 | $60,000.00 | +1.0% | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Casamento Charles J71 | Director | Buy | 5,000 | $6.00 | $30,000.00 | +7.9% | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Baum Mark L66 | Director | Buy | 10,000 | $6.00 | $60,000.00 | New | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Troutman William Wilson | CFO, Treasurer &Secretary | Buy | 5,000 | $6.00 | $30,000.00 | New | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Maier Paul V | Director | Buy | 5,000 | $6.00 | $30,000.00 | +9.1% | |
| Nov 15, 2018 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $16.60 | $415,122.00 | -3.6% | |
| Nov 15, 2018 | ETON Eton Pharmaceuticals, Inc. | Riedel Norbert G63 | Director | Buy | 5,000 | $6.00 | $30,000.00 | +9.1% | |
| Nov 15, 2018 | TLPH Talphera, Inc. | Edwards Mark G | Director | Buy | 20,700 | $2.82 | $58,376.07 | +12.9% | |
| Nov 15, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 258,000 | $4.90 | $1,265,232.00 | -8.1% | |
| Nov 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zasloff Michael A53 | Director | Sell | 29,278 | $20.39 | $596,949.14 | -49.5% | |
| Nov 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 16,015 | $20.41 | $326,854.66 | -4.2% | |
| Nov 14, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 5,000 | $20.23 | $101,166.50 | -12.4% | |
| Nov 14, 2018 | PBH Prestige Consumer Healthcare Inc. | Connors Timothy | EVP, Sales &Marketing | Sell | 74,707 | $38.96 | $2,910,901.82 | -27.8% | |
| Nov 13, 2018 | PRGO Perrigo Co Plc | Samuels Theodore R. II51 | Director | Buy | 3,500 | $65.40 | $228,901.75 | +85.0% | |
| Nov 13, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 2,460 | $113.41 | $278,978.76 | - | |
| Nov 13, 2018 | TLPH Talphera, Inc. | Asadorian Raffi | Chief Financial Officer | Buy | 5,000 | $3.13 | $15,646.00 | +11.9% | |
| Nov 13, 2018 | SIGA Siga Technologies Inc | Hruby Dennis E | VP &Chief Scientific Officer | Sell | 50,000 | $5.17 | $258,262.67 | -10.5% | |
| Nov 13, 2018 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 184,000 | $4.77 | $877,588.00 | -0.5% | |
| Nov 12, 2018 | NBIX Neurocrine Biosciences Inc | Pops Richard F57 | Director | Sell | 4,123 | $103.30 | $425,892.71 | -10.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.